|

Multiple Sclerosis Clinical Trials in California

41 recruiting studies across 7 cities

Browse by City

San Francisco
21 trials
San Jose
20 trials
Long Beach
16 trials
Los Angeles
16 trials
San Diego
9 trials
Sacramento
2 trials
Fresno
1 trial

All Trials in California

Phase
Trial Phase Dist.
Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS)N/A<1 mi
TSC Biosample Repository and Natural History Database—<1 mi
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention StudyPhase 2<1 mi
MS-ResearchBiomarkerS—<1 mi
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic SclerosisPhase 2<1 mi
Central Vein Sign in Multiple Sclerosis Extension StudyN/A<1 mi
Study of COYA 302 for the Treatment of ALSPhase 2<1 mi
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPhase 1<1 mi
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisPhase 3<1 mi
PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSPhase 2<1 mi
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy VolunteersPhase 1/2<1 mi
Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyPhase 1/2<1 mi
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk—<1 mi
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS—<1 mi
Care in Multiple Sclerosis (MS)—<1 mi
ECoG BMI for Motor and Speech ControlN/A<1 mi
Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)—<1 mi
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)Phase 2<1 mi
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical IllnessesPhase 2<1 mi
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)—1 mi
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisPhase 37 mi
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple SclerosisPhase 37 mi
A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisPhase 37 mi
AMX0114 in Adult Participants With Amyotrophic Lateral SclerosisPhase 111 mi
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)Phase 211 mi
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune DisordersPhase 111 mi
Kesimpta (Ofatumumab) Pregnancy Registry—11 mi
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent—11 mi
A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease—14 mi
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)Phase 316 mi
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple SclerosisPhase 116 mi
AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe EpilepsyPhase 1/216 mi
A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple SclerosisPhase 117 mi
A Study of AZD0120 in Autoimmune DiseasesPhase 117 mi
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of UblituximabPhase 320 mi
Obe-cel in Refractory Progressive Forms of Multiple SclerosisPhase 122 mi
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.Phase 322 mi
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)Phase 122 mi
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)Phase 333 mi
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)Phase 233 mi
Entire-body PET Scans for Multiple SclerosisEarly 135 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.